Spinal Cord Stimulation Market and Globus’ Acquisition of Nevro

The spinal cord stimulation (SCS) market is undergoing a significant transformation, driven by technological advancements and an increasing demand for non-pharmacological solutions to chronic pain. With rising concerns about opioid use and side effects, the adoption of spinal cord stimulation devices has surged as a safer, drug-free alternative. This shift is exemplified by recent industry developments, including Globus Medical’s acquisition of Nevro, a company specializing in neuromodulation solutions. This deal, valued at approximately $250 million, marks an important move by Globus to expand into the growing neuromodulation space, particularly in the SCS market.

This article explores the factors driving the growth of the spinal cord stimulation market, the key players shaping its future, and the technological innovations that are poised to redefine the way chronic pain is managed.

A Deep Dive into the Spinal Cord Stimulation Market

Why Spinal Cord Stimulation?

Chronic pain continues to be one of the most challenging health issues worldwide. It affects approximately 20% of adults globally, with an even higher incidence in the United States, where 24% of adults suffer from chronic pain. For years, spinal cord stimulation has served as an effective treatment option for patients who have not found relief through conventional therapies. By delivering electrical impulses to the spinal cord, SCS devices help mask pain signals before they reach the brain.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/spinal-cordstimulation-market-and-globus-acquisition-of-nevro